Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Blattmann, Claudia ^b,c,d   Oertel, Susanne ^a,c   Thiemann, Markus ^b,c   Dittmar, Anne ^a,c   Roth, Eva ^b,c   Kulozik, Andreas E ^a,b,c   Ehemann, Volker ^a   Weichert, Wilko ^a,c   Huber, Peter E ^c   Stenzinger, Albrecht ^a   Debus, Jürgen ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d German Cancer Research Center Department of Radiation Oncology ^*  (Germany)

Author keywords

Carbon ion radiotherapy; Histone deacetylase inhibition; Mouse model; Osteosarcoma; Radiosensitization; Suberoylanilide hydroxamic acid

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DIMETHYL SULFOXIDE; PROTEIN P53; VORINOSTAT; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HEAVY ION; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TUMOR PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL DENSITY; CELL PROLIFERATION; CHEMOSENSITIZATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; ION THERAPY; KHOS 24OS CELL LINE; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; RADIATION DOSE; TREATMENT DURATION; TUMOR NECROSIS; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; BONE TUMOR; CELL DIVISION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; SCID MOUSE; SUBCUTANEOUS TISSUE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEAVY ION RADIOTHERAPY; HEAVY IONS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, SCID; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; RADIATION TOLERANCE; SUBCUTANEOUS TISSUE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938827689     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0455-z     Document Type: Article

References (34)

1. Schardt D, Elsässer T, Schulz-Ertner D. Heavy-ion tumor therapy: Physical and radio-biological benefits. Rev Mod Phys. 2010;82:383.
2. Hundsdoerfer P, Albrecht M, Rühl U, Fengler R, Kulozik AE, Henze G. Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma. Eur J Cancer. 2009;45(14):2447-51.
3. Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion therapy in patients with non-resectable osteosarcomas. BMC Cancer. 2010;10:96.
4. Sugahara S, Kamada T, Imai R, Tsuji H, Kameda N, Okada T, et al. Carbon ion radiotherapy for localized primary sarcoma of the extremities: results of a phase I/II trial. Working group for the bone and soft tissue sarcomas. Radiother Oncol. 2012;105(2):226-31.
5. Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Working group for bone and soft tissue sarcomas. Cancer. 2012;118(18):4555-63.
6. Combs SE, Kessel KA, Herfarth K, Jensen A, Oertel S, Blattmann C, et al. Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. Radiat Oncol. 2012;7:170.
7. Perego P, Zuco V, Gatti L, Zunino F. Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol. 2012;83(8):987-94.
8. Entin-Meer M, Yang X, Vandenburg SR, Lamborn KR, Nudelman A, Rephaeli A, et al. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol. 2007;9:82-8.
9. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K. Radiosensitization by SAHA in experimental colorectal carcinoma models - in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys. 2009;74:546-52.
10. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, et al. Histone deacetylase inhibitors radiosensitize human melanoma by suppressing DNA repair activity. Clin Cancer Res. 2005;11:4912-22.
11. Thiemann M, Oertel S, Ehemann V, Weichert W, Stenzinger A, Bischof M, et al. In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat Oncol. 2012;7:52.
12. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs. 2014;25(2):140-9.
13. Blattmann C, Thiemann M, Stenzinger A, Christmann A, Roth E, Ehemann V, et al. Radiosensitization by Histone Deacetylase inhibition in an Osteosarcoma mouse model. Strahlenther Onkol. 2013;189(11):957-66.
14. Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys. 2010;78:237-45.
15. Oertel S, Thiemann M, Richter K, Weber KJ, Huber PE, Perez RL, et al. Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sacroma cell lines. Radiat Oncol. 2011;6:119.
16. Battmann C, Thiemann T, Stenzinger A, Weichert W, Bischof M, Lopez Perez R, et al. Radiosensitization by Histone Deacetylase Inhibition in an Osteosarcoma mouse model. Strahlenther Onkol. 2013;189(11):957-66.
17. Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M. Bone tumors in adolescents and young adults. Curr Treat Options Oncol. 2008;9:67-80.
18. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-90.
19. Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the national institutes of health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med. 2011;15:2735.
20. Bots M. R.W. Johnstone, Rational combinations using HDAC inhibitors. Clin. Cancer Res. 2009;15:3970-7.
21. Jensen AD, Münter MW, Debus J. Review of clinical experience with ion beam radiotherapy. Br J Radiol. 2011;84(Spec No 1):35-47.
22. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Birn. Proc Natl Acad Sci U S A. 2005;44:16090-5.
23. Lee CK, Wang S, Huang X, Ryder J, Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010;296:233-40.
24. D'Acunto CW, Fontanella B, Rodriquez M, Taddei M, Parente L, Petrella A. Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1. Cancer Lett. 2010;295:85-91.
25. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009;280:125-33.
26. Dickinson M, Johnstone RW. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010;28:3-20.
27. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem. 2003;278:12579-89.
28. Johnstone RW, Licht JD. Histone seacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell. 2003;4:13-8.
29. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604.
30. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol. 2006;26:2782-90.
31. Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T, et al. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol. 2010;37:787-95.
32. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, et al. MK-1775, a novel wee1 kinase inhibitor radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011;17:5638-48.
33. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev. 2006;5:769-84.
34. Mottet D, Castronovo V. Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr Cancer Drug Targets. 2010;10(8):898-913.